

1: Kim YS, Oka S, Chetchotisakd P, Clarke A, **Supparatpinyo K**, Avihingsanon A, Ratanasuwan W, Kiertiburanakul S, Ruxrungtham K, Yang S, Guo S, Liu Y, Das M, Tran D, McColl D, Corales R, Nguyen C, Piontkowsky D. Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials. HIV Res Clin Pract. 2019 Jul 8;1-9. doi: 10.1080/15284336.2019.1589232. [Epub ahead of print] PubMed PMID: 31303140.

2: Laksananun N, Praparattanapan J, Kotarathitum W, **Supparatpinyo K**, Chaiwarith R. Immunogenicity and safety of 4 vs. 3 standard doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody. AIDS Res Ther. 2019 May 3;16(1):10. doi: 10.1186/s12981-019-0225-3. PubMed PMID: 31053142; PubMed Central PMCID: PMC6498566.

3: Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, **Supparatpinyo K**, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808. PubMed PMID: 30865794; PubMed Central PMCID: PMC6563914.

4: Folschweiller N, Behre U, Dionne M, Durando P, Esposito S, Ferguson L, Ferguson M, Hillemanns P, McNeil SA, Peters K, Ramjattan B, Schwarz TF, **Supparatpinyo K**, Suryakirian PV, Janssens M, Moris P, Decreux A, Poncelet S, Struyf F. Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human

HPV-16/18 Vaccine. J Infect Dis. 2019 May 5;219(11):1799-1803. doi: 10.1093/infdis/jiy743.

PubMed PMID: 30715452; PubMed Central PMCID: PMC6500548.

5: Robertson KR, Jiang H, Kumwenda J, **Supparatpinyo K**, Marra CM, Berzins B, Hakim J, Sacktor N, Campbell TB, Schouten J, Mollan K, Tripathy S, Kumarasamy N, La Rosa A, Santos B, Silva MT, Kanyama C, Firnhhaber C, Murphy R, Hall C, Marcus C, Naini L, Masih R, Hosseinipour MC, Mngqibisa R, Badal-Faesen S, Yosief S, Vecchio A, Nair A; AIDS Clinical Trials Group. HIV Associated Neurocognitive Impairment in Diverse Resource Limited Settings. Clin Infect Dis. 2018 Sep 13. doi: 10.1093/cid/ciy767. [Epub ahead of print] PubMed PMID: 30219843; PubMed Central PMCID: PMC6495019.

6: Robertson K, Oladeji B, Jiang H, Kumwenda J, **Supparatpinyo K**, Campbell T, Hakim J, Tripathy S, Hosseinipour M, Marra CM; 5199 study team, Kumarasamy N, Evans S, Vecchio A, La Rosa A, Santos B, Silva MT, Montano S, Kanyama C, Firnhhaber C, Price R, Marcus C, Berzins B, Masih R, Lalloo U, Sanne I, Yosief S, Walawander A, Nair A, Sacktor N, Hall C; AIDS Clinical Trials Group. HIV-1 and TB Co-infection in Multinational Resource Limited Settings: Increased neurological dysfunction. Clin Infect Dis. 2018 Aug 20. doi: 10.1093/cid/ciy718. [Epub ahead of print] PubMed PMID: 30137250; PubMed Central PMCID: PMC6495021.

7: Shivakoti R, Ewald ER, Gupte N, Yang WT, Kanyama C, Cardoso SW, Santos B, **Supparatpinyo K**, Badal-Faesen S, Lama JR, Lalloo U, Zulu F, Pawar JS, Riviere C, Kumarasamy N, Hakim J, Pollard R, Detrick B, Balagopal A, Asmuth DM, Semba RD, Campbell TB, Golub J, Gupta A; NWCS 319 and ACTG PEARLS Study Team. Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial. Clin Nutr. 2019 Jun;38(3):1303-1309. doi: 10.1016/j.clnu.2018.05.014. Epub 2018 May 29. PubMed

PMID: 29885777; PubMed Central PMCID: PMC6265110.

8: Rattanathammethee K, Chawansuntati K, Chaiwarith R, Praparattanapan J, **Supparatpinyo K**, Wipasa J. Dot enzyme-linked immunosorbent assay strip as a screening tool for detection of autoantibody to interferon gamma in sera of suspected cases of adult-onset immunodeficiency. J Clin Lab Anal. 2018 Sep;32(7):e22460. doi: 10.1002/jcla.22460. Epub 2018 Apr 22. PubMed PMID: 29682788.

9: Chawansuntati K, Chaiklang K, Chaiwarith R, Praparattanapan J, **Supparatpinyo K**, Wipasa J. Hepatitis B Vaccination Induced TNF- α - and IL-2-Producing T Cell Responses in HIV- Healthy Individuals Higher than in HIV+ Individuals Who Received the Same Vaccination Regimen. J Immunol Res. 2018 Feb 27;2018:8350862. doi: 10.1155/2018/8350862. eCollection 2018. PubMed PMID: 29682590; PubMed Central PMCID: PMC5848135.

10: Wipasa J, Chaiwarith R, Chawansuntati K, Praparattanapan J, Rattanathammethee K, **Supparatpinyo K**. Characterization of anti-interferon- γ antibodies in HIV-negative immunodeficient patients infected with unusual intracellular microorganisms. Exp Biol Med (Maywood). 2018 Apr;243(7):621-626. doi: 10.1177/1535370218764086. Epub 2018 Mar 7. PubMed PMID: 29512397; PubMed Central PMCID: PMC6582397.

11: Wongtrakul J, Thongtan T, Roytrakul S, Praparattanapan J, Wipasa J, Kumrapich B, **Supparatpinyo K**. Identification of novel biomarkers for adult-onset-immunodeficiency (AOID) syndrome using serum proteomics. Asian Pac J Trop Med. 2017 May;10(5):466-472. doi: 10.1016/j.apjtm.2017.05.014. Epub 2017 May 18. PubMed PMID: 28647184.

12: Celum C, Hong T, Cent A, Donnell D, Morrow R, Baeten JM, Firnhaber C, Grinsztejn B, Hosseinipour MC, Lalloo U, Nyirenda M, Riviere C, Sanchez J, Santos B, **Supparatpinyo K**, Hakim J, Kumarasamy N, Campbell TB; ACTG PEARLS/A5175 Team. Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. *J Infect Dis.* 2017 Mar 15;215(6):907-910. doi: 10.1093/infdis/jix029. PubMed PMID: 28453835; PubMed Central PMCID: PMC5406847.

13: Wongtrakul J, Paemanee A, Wintachai P, Thepparit C, Roytrakul S, Thongtan T, Janphen K, **Supparatpinyo K**, Smith DR. Nevirapine induces apoptosis in liver (HepG2) cells. *Asian Pac J Trop Med.* 2016 Jun;9(6):547-53. doi: 10.1016/j.apjtm.2016.04.015. Epub 2016 Apr 16. PubMed PMID: 27262065.

14: Chaiwarith R, Praparattanapan J, Nuket K, Kotarathitithum W, **Supparatpinyo K**. Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand. *BMC Infect Dis.* 2016 Apr 30;16:190. doi: 10.1186/s12879-016-1499-x. PubMed PMID: 27138005; PubMed Central PMCID:PMC4852403.

15: Robbins NM, Chaiklang K, **Supparatpinyo K**. Better Antiretroviral Central Nervous System Penetration is Not Associated with Reduced Chronic Pain in People Living with Human Immunodeficiency Virus. *Ant infect Agents.* 2016;14(1):38-46. PubMed PMID: 27088075; PubMed Central PMCID: PMC4831626.

16: Tan TY, Hsu LY, Alejandria MM, Chaiwarith R, Chinniah T, Chayakulkeeree M, Choudhury S, Chen YH, Shin JH, Kiratisin P, Mendoza M, Prabhu K, **Supparatpinyo K**, Tan AL, Phan XT, Tran TT, Nguyen GB, Doan MP, Huynh VA, Nguyen SM, Tran TB, Van Pham H. Antifungal susceptibility of invasive *Candida* bloodstream isolates from the Asia-Pacific region. *Med Mycol*. 2016 Jul 1;54(5):471-7. doi: 10.1093/mmy/myv114. Epub 2016 Feb 11. PubMed PMID: 26868904.

17: Robertson K, Jiang H, Evans SR, Marra CM, Berzins B, Hakim J, Sacktor N, Silva MT, Campbell TB, Nair A, Schouten J; 5271 study team, Kumwenda J, **Supparatpinyo K**, Tripathy S, Kumarasamy N, la Rosa A, Montano S, Mwafongo A, Firnhaber C, Sanne I, Naini L, Amod F, Walawander A; AIDS Clinical Trials Group. International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271. *J Neurovirol*. 2016 Aug;22(4):472-8. doi: 10.1007/s13365-015-0415-2. Epub 2016 Jan 5. PubMed PMID: 26733457; PubMed Central PMCID: PMC4981921.

18: Chruewkamlow N, Mahasongkram K, Pata S, Chaiwarith R, Salee P, **Supparatpinyo K**, Kasinrerker W. Immune Alterations in Patients with Anti-Interferon- γ Autoantibodies. *PLoS One*. 2016 Jan 4;11(1):e0145983. doi: 10.1371/journal.pone.0145983. eCollection 2016. PubMed PMID: 26727515; PubMed Central PMCID: PMC4699769.

19: Boyd MA, Moore CL, Molina JM, Wood R, Madero JS, Wolff M, Ruxrungtham K, Losso M, Renjifo B, Teppler H, Kelleher AD, Amin J, Emery S, Cooper DA; SECOND-LINE study group. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE

trial: an exploratory analysis. Lancet HIV. 2015 Feb;2(2):e42-51. doi: 10.1016/S2352-018(14)00061-7. Epub 2015 Jan 20. PubMed PMID: 26424460.

20: INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20. PubMed PMID: 26192873; PubMed Central PMCID: PMC4569751.

21: Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, **Supparatpinyo K**, Mohapi L, Gupta A, Benson CA, Kim P, Fletcher CV; AIDS Clinical Trials Group A5279 Study Team. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis. 2015 Oct 15;61(8):1322-7. doi: 10.1093/cid/civ464. Epub 2015 Jun 16. PubMed PMID: 26082504; PubMed Central PMCID: PMC4583578.

22: Pinyopornpanish K, Chaiwarith R, Pantip C, Keawvichit R, Wongworapat K, Khamnoi P, **Supparatpinyo K**, Sirisanthana T. Comparison of Xpert MTB/RIF Assay and the Conventional Sputum Microscopy in Detecting Mycobacterium tuberculosis in Northern Thailand. Tuberc Res Treat. 2015;2015:571782. doi: 10.1155/2015/571782. Epub 2015 Apr 30. PubMed PMID: 26064681; PubMed Central PMCID: PMC4430669.

- 23: Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R; ENCORE1 Study Group. Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther. 2015 Oct;98(4):406-16. doi: 10.1002/cpt.156. Epub 2015 Jul 14. PubMed PMID: 26044067; PubMed Central PMCID: PMC4744681.
- 24: Balagopal A, Asmuth DM, Yang WT, Campbell TB, Gupte N, Smeaton L, Kanyama C, Grinsztejn B, Santos B, **Supparatpinyo K**, Badal-Faesen S, Lama JR, Lalloo UG, Zulu F, Pawar JS, Riviere C, Kumarasamy N, Hakim J, Li XD, Pollard RB, Semba RD, Thomas DL, Bollinger RC, Gupta A; ACTG PEARLS and NWCS 319 Study team. Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study. J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):163-71. doi: 10.1097/QAI.0000000000000696. PubMed PMID: 26017661; PubMed Central PMCID: PMC4573329.
- 25: Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczar D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S; GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15. Erratum in: Lancet. 2016 Apr 30;387(10030):1816. PubMed PMID: 25890673.

26: ENCORE1 Study Group, Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S, Mohapi L, Crabtree-Ramirez B, Jessen H, Kumar S, Winston A, Lee MP, Belloso W, Cooper DA, Emery S. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. *Lancet Infect Dis.* 2015 Jul;15(7):793-802. doi: 10.1016/S1473-3099(15)70060-5. Epub 2015 Apr 12. Erratum in: *Lancet Infect Dis.* 2015 Jul;15(7):761. PubMed PMID: 25877963.

27: Kingkeow D, Srithep S, Praparattanapan J, **Supparatpinyo K**, Pornprasert S. Thymic Function during 12 Months of Highly Active Antiretroviral Therapy in Thai HIV-Infected Patients with Normal and Slow Immune Recovery. *Jpn J Infect Dis.* 2015;68(5):353-6. doi: 10.7883/yoken.JJID.2014.237. Epub 2015 Feb 13. PubMed PMID: 25720642.

28: INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. *HIV Med.* 2015 Apr;16 Suppl 1:1-9. doi: 10.1111/hiv.12227. PubMed PMID: 25711317; PubMed Central PMCID: PMC4347998.

29: Kumarasamy N, Aga E, Ribaud HJ, Wallis CL, Katzenstein DA, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, **Supparatpinyo K**, Badal-Faesen S, Bartlett JA. Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230. *Clin Infect Dis.* 2015 May 15;60(10):1552-8. doi: 10.1093/cid/civ109. Epub 2015 Feb 18. PubMed PMID: 25694653; PubMed Central PMCID: PMC4425828.

30: Kantor R, Smeaton L, Vardhanabhuti S, Hudelson SE, Wallis CL, Tripathy S, Morgado MG, Saravanan S, Balakrishnan P, Reitsma M, Hart S, Mellors JW, Halvas E, Grinsztejn B, Hosseinipour MC, Kumwenda J, La Rosa A, Lalloo UG, Lama JR, Rassool M, Santos BR, **Supparatpinyo K**, Hakim J, Flanigan T, Kumarasamy N, Campbell TB, Eshleman SH; AIDS Clinical Trials Group (ACTG) A5175 Study Team. Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial. Clin Infect Dis. 2015 May 15;60(10):1541-9. doi: 10.1093/cid/civ102. Epub 2015 Feb 13. PubMed PMID: 25681380; PubMed Central PMCID: PMC4425827.

31: Wongtrakul J, Thongtan T, Roytrakul S, Kumrapich B, Janphen K, Praparattanapan J, **Supparatpinyo K**, Smith DR. Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine. Dis Markers. 2014;2014:315824. doi: 10.1155/2014/315824. Epub 2014 Dec 17. PubMed PMID: 25580050; PubMed Central PMCID: PMC4280805.

32: Pothirat T, Tantiworawit A, Chaiwarith R, Jariyapan N, Wannasan A, Siriyasatien P, **Supparatpinyo K**, Bates MD, Kwakye-Nuako G, Bates PA. First isolation of Leishmania from Northern Thailand: case report, identification as Leishmania martiniquensis and phylogenetic position within the Leishmania enriettii complex. PLoS Negl Trop Dis. 2014 Dec 4;8(12):e3339. doi: 10.1371/journal.pntd.0003339. eCollection 2014 Dec. PubMed PMID: 25474647; PubMed Central PMCID: PMC4256172.

33: Touzard Romo F, Smeaton LM, Campbell TB, Riviere C, Mngqibisa R, Nyirenda M, **Supparatpinyo K**, Kumarasamy N, Hakim JG, Flanigan TP. Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). HIV Clin Trials. 2014 Nov-Dec;15(6):246-60. doi: 10.1310/hct1506-246. PubMed PMID: 25433664; PubMed Central PMCID: PMC4357257.

34: Wipasa J, Wongkulab P, Chawansuntati K, Chaiwarit R, **Supparatpinyo K**. Cellular immune responses in HIV-negative immunodeficiency with anti-interferon- γ antibodies and opportunistic intracellular microorganisms. PLoS One. 2014 Oct 20;9(10):e110276. doi: 10.1371/journal.pone.0110276. eCollection 2014. PubMed PMID: 25329064; PubMed Central PMCID: PMC4203775.

35: Safren SA, Biello KB, Smeaton L, Mimiaga MJ, Walawander A, Lama JR, Rana A, Nyirenda M, Kayoyo VM, Samaneka W, Joglekar A, Celentano D, Martinez A, Remmert JE, Nair A, Lalloo UG, Kumarasamy N, Hakim J, Campbell TB; PEARLS (ACTG A5175) Study Team. Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS One. 2014 Aug 25;9(8):e104178. doi: 10.1371/journal.pone.0104178. eCollection 2014. PubMed PMID: 25153084; PubMed Central PMCID: PMC4143224.

36: Chaiwarith R, Vongsanim S, **Supparatpinyo K**. Cryptococcal meningitis in HIV-infected patients at Chiang Mai University Hospital: a retrospective study. Southeast Asian J Trop Med Public Health. 2014 May;45(3):636-46. PubMed PMID: 24974648.

37: Chaiklang K, Wipasa J, Chaiwarith R, Praparattanapan J, **Supparatpinyo K**. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial. PLoS One. 2013 Nov 12;8(11):e80409. doi: 10.1371/journal.pone.0080409. eCollection 2013. PubMed PMID: 24265819; PubMed Central PMCID: PMC3827227.

38: Kawila R, Chaiwarith R, **Supparatpinyo K**. Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study. BMC Infect Dis. 2013 Oct 5;13:464. doi: 10.1186/1471-2334-13-464. PubMed PMID: 24094273; PubMed Central PMCID: PMC3851520.

39: Wongkulab P, Wipasa J, Chaiwarith R, **Supparatpinyo K**. Autoantibody to interferon-gamma associated with adult-onset immunodeficiency in non-HIV individuals in Northern Thailand. PLoS One. 2013 Sep 27;8(9):e76371. doi: 10.1371/journal.pone.0076371. eCollection 2013. PubMed PMID: 24086734; PubMed Central PMCID: PMC3785451.

40: SECOND-LINE Study Group, Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A, Kerr S, Sohn AH, Teppler H, Van de Steen O, Molina JM, Emery S, Cooper DA. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet. 2013 Jun 15;381(9883):2091-9. doi: 10.1016/S0140-6736(13)61164-2. PubMed PMID: 23769235.

- 41: Dokuta S, Utaipat U, Praparattanapan J, Keitkarn J, Maneekarn N, Sirisanthana T, **Supparatpinyo K**. Improvement of the oligonucleotide ligation assay for detection of the M184V drug-resistant mutation in patients infected with human immunodeficiency virus type 1 subtype CRF01_AE. J Virol Methods. 2013 Jun;190(1-2):20-8. doi: 10.1016/j.jviromet.2013.03.016. Epub 2013 Apr 3. PubMed PMID: 23562659.
- 42: Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P; STARTMRK Investigators. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013 May 1;63(1):77-85. doi: 10.1097/QAI.0b013e31828ace69. PubMed PMID: 23412015.
- 43: Chaiwarith R, Praparattanapan J, Nuntachit N, Kotarathitithum W, **Supparatpinyo K**. Discontinuation of primary and secondary prophylaxis for opportunistic infections in HIV-infected patients who had CD4+ cell count <200 cells/mm³ but undetectable plasma HIV-1 RNA: an open-label randomized controlled trial. AIDS Patient Care STDS. 2013 Feb;27(2):71-6. doi: 10.1089/apc.2012.0303. PubMed PMID: 23373662.
- 44: Orkin C, DeJesus E, Khanlou H, Stoeckl A, **Supparatpinyo K**, Lathouwers E, Lefebvre E, Opsomer M, Van de Casteele T, Tomaka F. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. HIV Med. 2013 Jan;14(1):49-59. doi: 10.1111/j.1468-1293.2012.01060.x. Epub 2012 Oct 23. PubMed PMID: 23088336.

45: Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K; HIV STAR Study Group. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. *Antivir Ther.* 2012;17(7):1351-61. doi: 10.3851/IMP2443. Epub 2012 Jul 2. Erratum in: *Antivir Ther.* 2012;17(7):1389-90. PubMed PMID: 23075703.

46: Praparattanapan J, Kotarathitithum W, Chaiwarith R, Nuntachit N, Sirisanthana T, **Supparatpinyo K**. Resistance-associated mutations after initial antiretroviral treatment failure in a large cohort of patients infected with HIV-1 subtype CRF01_AE. *Curr HIV Res.* 2012 Dec;10(8):647-52. PubMed PMID: 23061604.

47: Robbins NM, Chaiklang K, **Supparatpinyo K**. Undertreatment of pain in HIV+ adults in Thailand. *J Pain Symptom Manage.* 2013 Jun;45(6):1061-72. doi: 10.1016/j.jpainsymman.2012.06.010. Epub 2012 Sep 29. PubMed PMID: 23026546; PubMed Central PMCID: PMC3568442.

48: Aupibul L, Chotirosniramit N, Sugandhavesa P, Kosashunhanan N, Thetket S, Supindham T, Piyamongkol W, **Supparatpinyo K**. Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand. *Curr HIV Res.* 2012 Dec;10(8):653-60. PubMed PMID: 22950382.

49: Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, **Supparatpinyo K**, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim JG; PEARLS study team of the ACTG. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med. 2012;9(8):e1001290. Epub 2012 Aug 14. PubMed PMID: 22936892; PubMed Central PMCID: PMC3419182.

50: DeJesus E, Rockstroh JK, Lennox JL, Saag MS, Lazzarin A, Zhao J, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P; STARTMRK Investigators. Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. HIV Clin Trials. 2012 Jul-Aug;13(4):228-32. doi: 10.1310/hct1304-228. Erratum in: HIV Clin Trials. 2012 Sep-Oct;13(5):preceding 233. PubMed PMID: 22849964.

51: Limmahakhun S, Chaiwarith R, Nuntachit N, Sirisanthana T, **Supparatpinyo K**. Treatment outcomes of patients co-infected with tuberculosis and HIV at Chiang Mai University Hospital, Thailand. Int J STD AIDS. 2012 Jun;23(6):414-8. doi: 10.1258/ijsa.2012.011291. PubMed PMID: 22807535.

52: Robertson K, Jiang H, Kumwenda J, **Supparatpinyo K**, Evans S, Campbell TB, Price R, Tripathy S, Kumarasamy N, La Rosa A, Santos B; 5199 study team, Silva MT, Montano S, Kanyama C, Faesen S, Murphy R, Hall C, Marra CM, Marcus C, Berzins B, Allen R, Housseinipour M, Amod F, Sanne I, Hakim J, Walawander A, Nair A; AIDS Clinical Trials Group. Improved neuropsychological

and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study. Clin Infect Dis. 2012 Sep;55(6):868-76. Epub 2012 Jun 1. PubMed PMID: 22661489; PubMed Central PMCID: PMC3491853.

53: Bartlett JA, Ribaud HJ, Wallis CL, Aga E, Katzenstein DA, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, **Supparatpinoy K**, Badal-Faesen S, Kallungal BA, Kumarasamy N. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS. 2012 Jul 17;26(11):1345-54. doi: 10.1097/QAD.0b013e328353b066. PubMed PMID: 22441252; PubMed Central PMCID: PMC3443745.

54: Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, Wu H, Johnson MA, Saag M, **Supparatpinoy K**, Crauwels H, Lefebvre E, Rimsky LT, Vanveggel S, Williams P, Boven K; ECHO Study Group; THRIVE Study Group. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naïve HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr. 2012 May 1;60(1):33-42. doi: 10.1097/QAI.0b013e31824d006e. PubMed PMID: 22343174.

55: Praparattanapan J, Kotarathitithum W, Chaiwarith R, Nuntachit N, Sirisanthana T, **Supparatpinoy K**, Tragoolpua Y. Impact of HIV-1 viral load on genotypic characteristics among patients failing non-nucleoside reverse transcriptase inhibitor-based first-line regimens in Northern Thailand. Southeast Asian J Trop Med Public Health. 2011 Jul;42(4):859-66. PubMed PMID: 22299468.

56: Chaiwarith R, Ounbang P, Khamwan C, Nuntachit N, Sirisanthana T, **Supparatpinyo K.**

Epidemiology of adult candidemia at Chiang Mai University Hospital. Southeast Asian J Trop Med Public Health. 2011 Nov;42(6):1505-14. PubMed PMID: 22299422.

57: Anekthananon T, Manosuthi W, Chetchotisakd P, Kiertiburanakul S, **Supparatpinyo K,** Ratanasuwan W, Pappas PG, Filler SG, Kopetskie HA, Nolen TL, Kendrick AS, Larsen RA; BAMSG 3-01 Study Team. Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients. Int J STD AIDS. 2011 Nov;22(11):665-70. doi: 10.1258/ijsa.2011.010538. PubMed PMID: 22096053.

58: Khienprasit N, Chaiwarith R, Sirisanthana T, **Supparatpinyo K.** Incidence and risk factors of antiretroviral treatment failure in treatment-naïve HIV-infected patients at Chiang Mai University Hospital, Thailand. AIDS Res Ther. 2011 Nov 7;8(1):42. doi: 10.1186/1742-6405-8-42. PubMed PMID: 22060823; PubMed Central PMCID: PMC3238297.

59: Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20;365(16):1482-91. doi: 10.1056/NEJMoa1013607. PubMed PMID: 22010914; PubMed Central PMCID: PMC3327101.

60: Eron JJ Jr, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, Young B, Katlama C, Gatell-Artigas JM, Arribas JR, Nelson M, Campbell H, Zhao J, Rodgers AJ, Rizk ML, Wenning L, Miller MD, Hazuda D, DiNubile MJ, Leavitt R, Isaacs R, Robertson MN, Sklar P, Nguyen BY; QDMRK Investigators. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. *Lancet Infect Dis.* 2011 Dec;11(12):907-15. doi: 10.1016/S1473-3099(11)70196-7. Epub 2011 Sep 18. Erratum in: *Lancet Infect Dis.* 2011 Dec;11(12):895. Dosage error in article text. PubMed PMID: 21933752.

61: Chaiwarith R, Fakthongyoo A, Praparattanapan J, Boonmee D, Sirisanthana T, **Supparatpinyo K.** Itraconazole vs fluconazole as a primary prophylaxis for fungal infections in HIV-infected patients in Thailand. *Curr HIV Res.* 2011 Jul;9(5):334-8. PubMed PMID: 21916838.

62: Wilkin A, Pozniak AL, Morales-Ramirez J, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K; TMC278-C204 Study Group. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naïve patients: week 192 results from a phase IIb randomized trial. *AIDS Res Hum Retroviruses.* 2012 May;28(5):437-46. doi: 10.1089/AID.2011.0050. Epub 2011 Oct 17. PubMed PMID: 21902621.

63: Robertson K, Kumwenda J, **Supparatpinyo K**, Jiang JH, Evans S, Campbell TB, Price RW, Murphy R, Hall C, Marra CM, Marcus C, Berzins B, Masih R, Santos B, Silva MT, Kumarasamy N, Walawander A, Nair A, Tripathy S, Kanyama C, Hosseinipour M, Montano S, La Rosa A, Amod F, Sanne I, Firnhaber C, Hakim J, Brouwers P; AIDS Clinical Trials Group. A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. *J Neurovirol.* 2011 Oct;17(5):438-47. doi: 10.1007/s13365-011-0044-3. Epub 2011 Jul 23. PubMed PMID: 21786076; PubMed Central PMCID: PMC3362044.

64: Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, **Supparatpinyo K**, Walmsley S, Crauwels H, Rinsky LT, Vanveggel S, Boven K; ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. *Lancet*. 2011 Jul 16;378(9787):238-46. doi: 10.1016/S0140-6736(11)60936-7. PubMed PMID: 21763936.

65: Chaiwarith R, Jullaket W, Bunchoo M, Nuntachit N, Sirisanthana T, **Supparatpinyo K**. *Streptococcus agalactiae* in adults at Chiang Mai University Hospital: a retrospective study. *BMC Infect Dis*. 2011 May 25;11:149. doi: 10.1186/1471-2334-11-149. PubMed PMID: 21612629; PubMed Central PMCID: PMC3123213.

66: Prasithsirikul W, Hanvanich M, Suwanagool S, Ratanasuwan W, Anekthananon T, Techasathit W, **Supparatpinyo K**, Viphagool A. Two-year safety and tolerability study of enfuvirtide use in salvage therapy of Thai HIV-1 experienced cases. *J Med Assoc Thai*. 2011 Mar;94(3):303-8. PubMed PMID: 21560837.

67: Praparattanapan J, Tragoolpua Y, Pathom-aree W, Kotarathitithum W, Chaiwarith R, Nuntachit N, Sirisanthana T, **Supparatpinyo K**. Current molecular epidemiology and recombination of HIV type 1 subtypes in northern Thailand. *AIDS Res Hum Retroviruses*. 2011 Nov;27(11):1201-6. doi: 10.1089/AID.2010.0257. Epub 2011 May 6. PubMed PMID: 21449850.

68: Chaiwarith R, Praparattanapan J, Nuntachit N, Kotarathitithum W, Sirisanthana T, **Supparatpinyo K**. Impact of the frequency of plasma HIV-1 RNA monitoring on the outcome of antiretroviral therapy. *Curr HIV Res*. 2011 Mar;9(2):82-7. PubMed PMID: 21361862.

69: Malan N, Su J, Mancini M, Yang R, Wirtz V, Absalon J, McGrath D; CASTLE Study Team. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study. *AIDS Care*. 2010 Jun;22(6):677-86. doi: 10.1080/09540120903334641. PubMed PMID: 20467943.

70: Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK Investigators. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. *J Acquir Immune Defic Syndr*. 2010 Sep;55(1):39-48. doi: 10.1097/QAI.0b013e3181da1287. Erratum in: *J Acquir Immune Defic Syndr*. 2011 Dec 1;58(4):e120. Dosage error in article text. PubMed PMID: 20404738; PubMed Central PMCID: PMC6065510.

71: Manosuthi W, Chetchotisakd P, Nolen TL, Wallace D, Sungkanuparph S, Anekthananon T, **Supparatpinyo K**, Pappas PG, Larsen RA, Filler SG, Andes D; BAMSG 3-01 Study Team. Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients. *HIV Med*. 2010 Apr;11(4):276-81. doi: 10.1111/j.1468-1293.2009.00778.x. Epub 2009 Dec 8. PubMed PMID: 20002501; PubMed Central PMCID: PMC3418324.

72: Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K; TMC278-C204 Study Group. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. *AIDS*. 2010 Jan 2;24(1):55-65. doi: 10.1097/QAD.0b013e32833032ed. PubMed PMID: 19926964.

73: Sungkanuparph S, Filler SG, Chetchotisakd P, Pappas PG, Nolen TL, Manosuthi W, Anekthananon T, Morris MI, **Supparatpinyo K**, Kopetskie H, Kendrick AS, Johnson PC, Sobel JD, Larsen RA. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. *Clin Infect Dis*. 2009 Sep 15;49(6):931-4. doi: 10.1086/605497. PubMed PMID: 19681708.

74: Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, Barnard RJ, Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. *Lancet*. 2009 Sep 5;374(9692):796-806. doi: 10.1016/S0140-6736(09)60918-1. Epub 2009 Aug 3. Erratum in: *Lancet*. 2009 Dec 19-2010 Jan 1;374(9707):2054. *Lancet*. 2009 Sep 5;374(9692):786. PubMed PMID: 19647866.

75: Manosuthi W, Sungkanuparph S, Anekthananon T, **Supparatpinyo K**, Nolen TL, Zimmer LO, Pappas PG, Larsen RA, Filler SG, Chetchotisakd P; BAMSG 3-01 Study Team. Effect of high-dose fluconazole on QT interval in patients with human immunodeficiency virus (HIV)-associated cryptococcal meningitis. *Int J Antimicrob Agents*. 2009 Nov;34(5):494-6. doi:

10.1016/j.ijantimicag.2009.05.009. Epub 2009 Jun 30. PubMed PMID: 19570657; PubMed Central PMCID: PMC2749459.

76: Chaiwarith R, Salee P, Kotarathitithum W, Sirisanthana T, **Supparatpinyo K**. Long-term CD4 cell count recovery among Thai naive HIV-infected patients initiating HAART at low CD4 cell count. Curr HIV Res. 2009 May;7(3):340-5. PubMed PMID: 19442132.

77: Pappas PG, Chetchotisakd P, Larsen RA, Manosuthi W, Morris MI, Anekthananon T, Sungkanuparph S, **Supparatpinyo K**, Nolen TL, Zimmer LO, Kendrick AS, Johnson P, Sobel JD, Filler SG. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2009 Jun 15;48(12):1775-83. doi: 10.1086/599112. PubMed PMID: 19441980.

78: Pornprasert S, Praparattanapan J, Khamwan C, Pawichai S, Pimsarn P, Samleerat T, Leechanachai P, **Supparatpinyo K**. Development of TaqMan real-time polymerase chain reaction for the detection and identification of *Penicillium marneffe*. Mycoses. 2009 Nov;52(6):487-92. doi: 10.1111/j.1439-0507.2008.01653.x. Epub 2009 Jan 9. PubMed PMID: 19207847.

79: Chaiwarith R, Pasogpakdee P, Salee P, Kanjanaratanakorn K, Sirisanthana T, **Supparatpinyo K**. Risk factors for extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* and *Escherichia coli* acquisition in a tertiary care teaching hospital in Thailand. J Hosp Infect. 2009 Mar;71(3):285-6. doi: 10.1016/j.jhin.2008.11.021. Epub 2009 Jan 20. PubMed PMID: 19157645.

80: Sungkanuparph S, Anekthananon T, Hiransuthikul N, Bowonwatanuwong C, **Supparatpinyo K**, Mootsikapun P, Chetchotisakd P, Kiertiburanakul S, Tansuphaswadikul S, Buppanharun W, Manosuthi W, Techasathit W, Ratanasuwan W, Tantisiriwat W, Suwanagool S, Leechawengwongs M, Ruxrungtham K; Thai AIDS Society. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai. 2008 Dec;91(12):1925-35. PubMed PMID: 19133532.

81: Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D; CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008 Aug 23;372(9639):646-55. doi: 10.1016/S0140-6736(08)61081-8. PubMed PMID: 18722869.

82: Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, **Supparatpinyo K**, Ruxrungtham K; Study Team. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. HIV Med. 2007 Nov;8(8):529-35. PubMed PMID: 17944686.

83: **Supparatpinyo K**, Schlamm HT. Voriconazole as therapy for systemic *Penicillium marneffei* infections in AIDS patients. Am J Trop Med Hyg. 2007 Aug;77(2):350-3. PubMed PMID: 17690411.

84: Kongkaew W, Siriarayaporn P, Leelayoova S, **Supparatpinyo K**, Areechokchai D, Duang-ngern P, Chanachai K, Sukmee T, Samung Y, Sridurongkathum P. Autochthonous visceral leishmaniasis: a report of a second case in Thailand. Southeast Asian J Trop Med Public Health. 2007 Jan;38(1):8-12. PubMed PMID: 17539239.

85: Boulware DR, Stauffer WM, Hendel-Paterson BR, Rocha JL, Seet RC, Summer AP, Nield LS, **Supparatpinyo K**, Chaiwarith R, Walker PF. Maltreatment of Strongyloides infection: case series and worldwide physicians-in-training survey. Am J Med. 2007 Jun;120(6):545.e1-8. PubMed PMID: 17524758; PubMed Central PMCID: PMC1950578.

86: Chaiwarith R, Wachirakaphan C, Kotarathitum W, Praparatanaphan J, Sirisanthana T, **Supparatpinyo K**. Sensitivity and specificity of using CD4+measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. Int J Infect Dis. 2007 Sep;11(5):413-6. Epub 2007 Feb 28. PubMed PMID: 17331776.

87: Chaiwarith R, Charoenyos N, Sirisanthana T, **Supparatpinyo K**. Discontinuation of secondary prophylaxis against penicilliosis marneffeii in AIDS patients after HAART. AIDS. 2007 Jan 30;21(3):365-7. PubMed PMID: 17255744.

88: Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S, Sutthent R, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, **Supparatpinyo K**, Horsakulthai M, Chasombat S, Ruxrungtham K; Study Team. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is

predominant. J Int Assoc Physicians AIDS Care (Chic). 2006 Dec;5(4):152-6. PubMed PMID: 17101807.

89: Krajaejun T, Sathapatayavongs B, Prachartam R, Nitiyanant P, Leelachaikul P, Wanachiwanawin W, Chaiprasert A, Assanasen P, Saipetch M, Mootsikapun P, Chetchotisakd P, Lekhakula A, Mitarnun W, Kalnauwakul S, **Supparatpinyo K**, Chaiwarith R, Chiewchanvit S, Tananuvat N, Srisiri S, Suankratay C, Kulwichit W, Wongsaisuwan M, Somkaew S. Clinical and epidemiological analyses of human pythiosis in Thailand. Clin Infect Dis. 2006 Sep 1;43(5):569-76. Epub 2006 Jul 13. PubMed PMID: 16886148.

90: Wangkaew S, Chaiwarith R, Tharavichitkul P, **Supparatpinyo K**. Streptococcus suis infection: a series of 41 cases from Chiang Mai University Hospital. J Infect. 2006 Jun;52(6):455-60. Epub 2006 May 11. PubMed PMID: 16690131.

91: Chaiwun B, Khunamornpong S, Sirivanichai C, Rangdaeng S, **Supparatpinyo K**, Settakorn J, Ya-in C, Thorner P. Lymphadenopathy due to *Penicillium marneffe* infection: diagnosis by fine needle aspiration cytology. Mod Pathol. 2002 Sep;15(9):939-43. PubMed PMID: 12218211.

92: Chariyalertsak S, **Supparatpinyo K**, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis. 2002 Jan 15;34(2):277-84. Epub 2001 Dec 7. PubMed PMID: 11740718.

93: **Supparatpinyo K**, Perriens J, Nelson KE, Sirisanthana T. A controlled trial of itraconazole to prevent relapse of *Penicillium marneffe*i infection in patients infected with the human immunodeficiency virus. N Engl J Med. 1998 Dec 10;339(24):1739-43. PubMed PMID: 9845708.

94: Sirisanthana T, **Supparatpinyo K**. Epidemiology and management of penicilliosis in human immunodeficiency virus-infected patients. Int J Infect Dis. 1998 Jul-Sep;3(1):48-53. Review. PubMed PMID: 9831676.

95: Sirisanthana T, **Supparatpinyo K**, Perriens J, Nelson KE. Amphotericin B and itraconazole for treatment of disseminated *Penicillium marneffe*i infection in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998 May;26(5):1107-10. PubMed PMID: 9597237.

96: Wheat J, Wheat H, Connolly P, Kleiman M, **Supparatpinyo K**, Nelson K, Bradsher R, Restrepo A. Cross-reactivity in Histoplasma capsulatum variety capsulatum antigen assays of urine samples from patients with endemic mycoses. Clin Infect Dis. 1997 Jun;24(6):1169-71. PubMed PMID: 9195077.

97: Chariyalertsak S, Sirisanthana T, **Supparatpinyo K**, Praparattanapan J, Nelson KE. Case-control study of risk factors for *Penicillium marneffe*i infection in human immunodeficiency virus-infected patients in northern Thailand. Clin Infect Dis. 1997 Jun;24(6):1080-6. PubMed PMID: 9195061.

98: Vanittanakom N, Mekaprateep M, Sittisombut N, **Supparatpinyo K**, Kanjanasthiti P, Nelson KE, Sirisanthana T. Western immunoblot analysis of protein antigens of *Penicillium marneffei*. J Med Vet Mycol. 1997 Mar-Apr;35(2):123-31. PubMed PMID: 9147272.

99: Chariyalertsak S, Sirisanthana T, **Supparatpinyo K**, Nelson KE. Seasonal variation of disseminated *Penicillium marneffei* infections in northern Thailand: a clue to the reservoir? J Infect Dis. 1996 Jun;173(6):1490-3. PubMed PMID: 8648227.

100: **Supparatpinyo K**, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated *Penicillium marneffei* infection in southeast Asia. Lancet. 1994 Jul 9;344(8915):110-3. PubMed PMID: 7912350.

101: **Supparatpinyo K**, Sirisanthana T. Disseminated *Penicillium marneffei* infection diagnosed on examination of a peripheral blood smear of a patient with human immunodeficiency virus infection. Clin Infect Dis. 1994 Feb;18(2):246-7. PubMed PMID: 8161635.

102: **Supparatpinyo K**, Nelson KE, Merz WG, Breslin BJ, Cooper CR Jr, Kamwan C, Sirisanthana T. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated *Penicillium marneffei* infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother. 1993 Nov;37(11):2407-11. PubMed PMID: 8285625; PubMed Central PMCID: PMC192399.

103: **Supparatpinyo K**, Chiewchanvit S, Hirunsri P, Baosoung V, Uthammachai C, Chaimongkol B, Sirisanthana T. An efficacy study of itraconazole in the treatment of *Penicillium marneffe*i infection. J Med Assoc Thai. 1992 Dec;75(12):688-91. PubMed PMID: 1339213.

104: **Supparatpinyo K**, Chiewchanvit S, Hirunsri P, Uthammachai C, Nelson KE, Sirisanthana T. *Penicillium marneffe*i infection in patients infected with human immunodeficiency virus. Clin Infect Dis. 1992 Apr;14(4):871-4. PubMed PMID: 1315586.